• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA actions in brief, May 2008

News
Article

Recent FDA approvals and indications (through May 2008) related to Janumet, PegIntron, Rebetol, Xyzal, Liquadd, and NovoLog.

The labeling for sitagliptin/metformin (Janumet, Merck) was updated to reflect an expanded indication. The agent is now approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

FDA approved labeling changes for peginterferon alfa-2b (PegIntron, Schering-Plough) and ribavirin (Rebetol, Schering-Plough) as combination therapy for the treatment of chronic hepatitis C infection. The labels now recommend weight-based dosing of ribavirin (800–1,400 mg/d) and a shorter 24-week course of the combination therapy for patients with chronic hepatitis C virus genotype 2 or 3. An oral solution of levocetirizine (Xyzal, UCB) was approved for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) and for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children aged ≥6 years.

FDA approved dextroamphetamine oral solution, 5 mg/5 mL (Liquadd, Auriga) for the treatment of attention- deficit/hyperactivity disorder (ADHD).

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.